Evidera
Malinda O'Donnell's work experience includes positions in various companies and roles. From 1997 to 2000, they worked as a Cryogenics specialist at Charles River Laboratories. From 2006 to 2012, they worked as a Senior Medical Writer at Custom Learning Designs, specializing in oncology learning systems. Since 2012, they have been with Evidera, initially as a Director of Payer Communications, where they managed market access communications materials and provided writing and communication support for payer ad boards. In 2015, they were promoted to Director of Market Access Communications, taking on additional responsibilities such as developing HEOR education and training programs and managing a team. Malinda then became a Senior Director in 2017, responsible for managing and developing a team of market access writers across North America. In 2019, they assumed the roles of General Manager and Executive Director of Market Access Communications at Evidera.
Malinda O'Donnell obtained their Bachelor of Science degree in Biology and Biotechnology from Worcester Polytechnic Institute, where they studied from 1999 to 2003. Following this, they pursued a Master of Science degree in Cell and Developmental Biology with a focus on Virology at the University of Colorado Anschutz Medical Campus, completing their studies from 2003 to 2006.
This person is not in any offices
Evidera
1 followers
Evidera is a business within Pharmaceutical Product Development, LLC, (PPD) a leading global contract research organization (CRO), and is the preeminent provider of evidence-based solutions to demonstrate the real-world effectiveness, safety, and value of biopharmaceutical and biotechnology products from early development through loss of exclusivity. We provide integrated scientific expertise and global operational capabilities to help you generate the evidence needed to optimize the market access and commercial potential of your products. Evidera was acquired by PPD in 2016 and originally created in 2013 as an independent company under the ownership of Symphony Technology Group following the acquisition of long-standing health economics, outcomes research, market access, epidemiology, and data analytics practices from United BioSource Corporation (UBC). Evidera has over 30 years of leadership and experience and its legacy brands include MEDTAP, Caro Research, Abt Bio-Pharmaceutical Solutions, MetaWorks, Total Healthcare Group, and Archimedes.